HMGCR Antibodies

Santa Cruz Biotechnology delivers a wide array of HMGCR monoclonal antibodies for research in cholesterol metabolism and related pathways. HMGCR monoclonal antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). 3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) plays a crucial role in the mevalonate pathway, which is essential for the biosynthesis of cholesterol and other isoprenoids. As a key regulatory enzyme, HMGCR is a target for statin drugs, which are widely used to manage cholesterol levels and reduce cardiovascular risk. Understanding the function and regulation of HMGCR is vital for advancing therapeutic strategies in lipid disorders and metabolic diseases. HMGCR research has significant implications for cardiovascular health and metabolic regulation. Investigating HMGCR activity patterns helps reveal new insights into cholesterol synthesis pathways. Current research focuses on understanding how HMGCR regulation affects various metabolic conditions. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing our understanding of cholesterol metabolism and its impact on human health.